Antihypertensive Activity and ADR Survey of Amlodipine and Telmisartan in Hypertension

Aim: Antihypertensive activity and ADR survey of amlodipine and telmisartan in hypertension.Objectives: To identify the combination activity of amlodipine and telmisartan in hypertensive patients.To know drug interaction with amlodipine and telmisartan.To find out other possible side effects or actions other than hypertension.To find out the therapeutic failures of combination treatment.To find out clinical trial data.To find out fixed dose combinations and dose frequency.Review all the information about their mode of action, pharmacological properties, general properties, chemical properties and detailed information about amlodipine and telmisartan.There is much more evidence that blood pressure (BP) control significantly reduces the risk of future cardiovascular events in patients with essential hypertension.However, BP control is strict and difficult to maintain, half of hypertensive patients fail to control BP on single-drug therapy.(3) Therefore, current guidelines recommend combinations of antihypertensive drugs that have complimentary modes of actions for the treatment of patients with acute or moderate hypertension.In this study, we examined in hypertensive patients controlled by the combination treatment with 5 mg amlodipine plus 40 mg telmisartan.Amlodipine, a thirdgeneration dihydropyridine CCB, is a racemic mixture consisting of the Renantiomer and S-enantiomer in a 1:1 ratio Amlodipine is an oral dihydropyridine calcium channel blocker.Amlodipine is available as amlodipine besylate, initially approved in 1987 by the Food and Drug Administration (FDA) Amlodipine is primarily administered orally and is available in 2.5 mg, 5 mg, and 10 mg tablets, amlodipine has the longest half-life at 30 to 50 hours.The benefit of such a long half-life is the ability to have once-daily dosing.(3) Telmisartan is an ARB, with a selective type 1 receptor blockade effect.The antihypertensive efficacy of telmisartan, administered once daily at doses of 20-160 mg in patients with mild-tomoderate essential hypertension, has been shown to be superior to that of placebo and comparable to that of other common antihypertensive agents.Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.The absolute bioavailability of telmisartan is dose-dependent.(1, 2, 3, 4) As per ADR survey, the side effect of amlodipine is higher than the telmisartan.They initially cause edema or swelling, gum hypertrophy, hypotension, etc.The severity of side effect has low not life-threatening condition occurs.